Author: Jessica Yingling

Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101

by on January 31, 2023

AB-101 is a cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers Granted Fast Track designation by U.S. FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell origin, in combination with rituximab SAN DIEGO, January 31, 2023 – Artiva Biotherapeutics, Inc., a clinical…

Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

by on November 10, 2022

Presentation of preclinical data for AB-101, a clinical-stage, ADCC-enhancer, allogeneic, off-the-shelf NK cell therapy candidate developed with Artiva’s AlloNKTM Platform Data highlights the optimized cell profile of AB-101 and combination data with monoclonal antibodies rituximab, obinutuzumab, cetuximab, and trastuzumab SAN DIEGO, November 10, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is…

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

by on November 3, 2022

Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patients Affimed’s AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patients AB-101 is a clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived NK cell manufactured at large…

Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition

by on November 3, 2022

Data describe the preclinical activity of AB-101, an allogeneic NK cell product candidate, in combination with CD38 therapeutic antibodies in multiple myeloma model systems without the need for CD38 editing SAN DIEGO, November 3, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK)…

Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

by on October 5, 2022

SAN DIEGO, October 5, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, announced today that an abstract highlighting further in vivo and in vitro preclinical data for AB-101, the Company’s clinical-stage ADCC-enhancer…

Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors

by on September 20, 2022

AB-201 is a novel and highly specific HER2-directed cell therapy candidate developed using Artiva’s proprietary CAR technology and scaled AlloNKTM manufacturing platform Clinical study of AB-201 in HER2-positive cancers is planned to initiate in 1H2023 SAN DIEGO, September 20, 2022 — Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective,…

Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities

by on June 13, 2022

52,000-square-foot corporate headquarters in San Diego with R&D and GMP manufacturing center Builds on current capability at Artiva’s partner, GC Cell’s facility in Republic of Korea Custom-built GMP manufacturing center further enables Artiva’s leadership position in scaled, off-the-shelf NK and CAR-NK therapeutic manufacturing for treatment of solid and hematological cancers SAN DIEGO, June 13, 2022…

Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer

by on June 6, 2022

SAN DIEGO, June 6, 2022 – Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer (NK) cell therapies that are safe and accessible to cancer patients, today announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer. As a highly respected drug development leader, Dr….

Artiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Board

by on May 5, 2022

SAN DIEGO, May 5, 2022 — Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, today announced the appointment of Edith A. Perez, M.D., as a member of the Company’s Board of Directors. In addition, Dr….

Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers

by on April 11, 2022

Artiva to provide clinical-grade NK cells from its AlloNKTM platform for assessment in combination with tri-specific NK-cell engagers SAN DIEGO, April 11, 2022 — Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an…